Intelligent Bio Solutions Advances FDA Clearance with Codeine Detection Study

Event summary

  • Intelligent Bio Solutions has initiated clinical studies to support FDA 510(k) submission for its drug screening system, focusing on codeine detection.
  • The study, conducted with Cliantha Research, will assess 40 adults and compare results with a predicate FDA-cleared device.
  • Full data analysis is expected by the end of March 2026, with results to be incorporated into the FDA submission package.
  • The U.S. drug screening market, valued in the billions, represents a significant commercial opportunity for the company's non-invasive technology.

The big picture

Intelligent Bio Solutions is positioning itself to enter the U.S. drug screening market, which generates billions annually. The company's non-invasive fingerprint-based technology offers advantages over traditional testing methods, including improved hygiene and rapid results. Success in securing FDA clearance could significantly expand its customer base, which currently includes construction, manufacturing, and drug treatment organizations outside the U.S.

What we're watching

Regulatory Pathway
Whether the clinical study results will meet FDA standards for 510(k) clearance and enable market entry.
Market Expansion
The pace at which Intelligent Bio Solutions can penetrate the U.S. drug screening market beyond forensic use.
Competitive Positioning
How the company's non-invasive technology will differentiate itself in a crowded market with established testing methods.